• P. N. Patsalos


Rufinamide (Fig. 1) corresponds chemically to 1-[(2,6-difluorophenyl) methyl]-1-hydro-1,23-triazole-4carboxamide with an empirical formula of C10H8F2N4O and a molecular weight of 238.19.


Valproic Acid Therapeutic Drug Monitoring Plasma Protein Binding Pharmacokinetic Interaction Glucuronide Metabolite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents a randomized placebo-controlled trial. Epilepsia. 2009;50:1899–909.PubMedCrossRefGoogle Scholar
  3. 3.
    May TW, Boor R, Rambeck B, Jurgens U, Korn-Merker E, Brandt C. Serum concentrations of rufinamide in children and adults with epilepsy the influence of dose, age, and comedication. Ther Drug Monit. 2011;33:214–21.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations